In an effort to define the roles of bone morphogenic proteins (BMPs) and fibroblast growth factors (FGFs) during chick limb development more closely, we have implanted beads impregnated with these growth factors into chick limb buds between stages 20 and 26. Embryos were sacrificed at the time the bone chondrocyte condensations first appear (stages 27-28). Implantation of beads containing BMPs at the earlier stages (20-22) caused apoptosis to occur, in the most severe cases leading to complete limb degeneration. Application of FGF4, either in the same, or in a different bead, prevented the BMP-induced apoptosis. We argue that the apoptosis observed on removal of the AER prior to stage 23 of development could be brought about by BMPs. The action of epithelial FGF in preventing BMP-mediated apoptosis in the mesenchyme would define a novel aspect of epithelial-mesenchymal interactions. Implanting the BMP4 beads into the core of the limb bud a day later (stages 25-26) caused intense chondrogenesis rather than apoptosis. FGF4 could again nullify this effect and by itself caused a reduction in bone size. This is the reverse of the functional relationship these growth factors have in mouse tooth specification (where it is BMP4 that inhibits the FGF8 function), and suggests that the balance between the effects of FGFs and BMPs could control the size of the chondrocyte precursor cell pool. In this way members of these two growth factor families could control the size of appendages when they are initially formed.
Introduction
Signalling centres have been identified which consist of an epithelium and adjacent mesenchyme whose interaction directs the local development of embryonic structures. One such centre is the distal tip of the growing vertebrate limb. This is bounded distally by the apical ectodermal ridge (AER), the removal of which results in limb truncations (Saunders, 1948) . However, replacement of the AER with acrylic beads which have been pre-soaked in fibroblast growth factor 4 (FGF4) apically and on the posterior margin of the bud results in normal outgrowth . The main function of the AER is therefore to control limb outgrowth by producing FGF4 (and other FGFs, e.g. Crossley et al., 1996) . The cells immediately beneath the AER constitute the progress zone, a region of uncommitted progenitor cells with a higher mitotic index than more proximal cells (Hornbruch and Wolpert, 1970; Summerbell et al., 1973) . The zone is maintained by the AER, and as outgrowth occurs the cells on the proximal margin move away from the influence of the AER. It is on leaving the progress zone that cells are thought to read their positional values and become committed (although initially not irreversibly) to a particular cell fate (Tickle et al., 1975) .
Cells in the progress zone initially synthesise bone morphogenic proteins (BMP2 and BMP4). These are members of the TGFb family of growth factors, which were originally identified as chondrogenic/osteoblastic agents from adult cattle bones that could induce bone at ectopic sites in rats (Urist, 1965; Wozney et al., 1988) . Mutations causing truncations to the Bmp5 and Gdf5 genes (the latter a close Bmp relative) have bone phenotypes (Kingsley et al., 1992; Storm et al., 1994) , showing that bone formation is a main function of these particular family members during embryogenesis.
However, gene-targeted Bmp4 homozygous null mutant mice have a variable phenotype, the most severely affected embryos degenerating without forming mesoderm (Winnier et al., 1995) demonstrating that BMP4 has functions other than specifying bone (for review see Hogan, 1996) .
The Bmp4 genes are initially transcribed in the cells of stage 16-17 chick wing fields, in both the ectoderm and mesenchyme, and expression continues in the whole of the limb bud until stages 18-19, whereupon it is gradually lost from the centre of the mesenchyme of the developing bud. By stage 24 very much lower levels of transcripts are present directly beneath the AER, and by stage 25 levels along the posterior margin of the limb bud are also reduced . Bmp2, however, is only expressed in the posterior mesenchyme, and is more prominently expressed in the ectoderm, and for longer in the AER than Bmp4 .
In the early chick limb bud, BMP2 (but not BMP4) has been shown to have an inhibitory effect on the mitogenic activity of FGF4 . At a similar stage of development (stages 20-22) BMP2-producing cells implanted under the anterior AER were partially able to reproduce the properties of Shh and the zone of polarising activity (ZPA) (Duprez et al., 1996a) , suggesting that BMPs Fig. 1 . Effects of BMPs on limb development. Acrylic beads were charged with rBMP2 and rBMP4 at various concentrations, and implanted into stage 20-22 chick limb buds. The embryos were left to develop for a further 2 days, until stage 27-28, when they were photographed before (left hand panel) and after (right) staining with Alcian blue (except (E,F), separate embryos). (A,B) Control embryos with beads washed with PBS. Beads soaked in (C) 660 mg/ml rBMP2; (D) 330 mg/ml rBMP2; (E-F) 330 mg/ml rBMP4; (G) 200 mg/ml rBMP4. Arrows indicate the position of the bead in each panel. BMP2 caused degeneration of the limb tissue immediately around the bead, and a delay in the production of the chondrogenic condensations of the radius and ulna, in comparison with the contralateral limb. BMP4 caused complete degeneration of the developing limb. Scale bar, 500 mm. produced in the ZPA might be involved in pattern formation. At slightly later stages (stages 25-26) BMP2 and BMP4 promote chondrogenesis (Duprez et al., 1996b) . We wished to assess more closely the role of BMPs at the early stages of limb development, and define the possible interaction with FGF4. To this end acrylic beads were charged with the different growth factors and implanted into stage 20-26 chick limb buds. We show that there is a short window, between stages 20 and 22 when ectopic application of BMPs to the core of the limb bud causes apoptosis. A day later (stages 25-26) BMP4 promotes chondrogenesis. Both the apoptotic and chondrogenic activities of BMP4 can be inhibited by FGF4, demonstrating the requirement for the correct balance between these growth factors to be maintained, both spatially and temporally, for normal limb development.
Results

Application of rBMPs causes limb abnormalities
After bead implantation at stages 20-22, embryos were left to develop for 2 days (stages 27-28) before photography and Alcian blue staining of chondrogenic condensations. The operation to implant control beads (containing phosphate-buffered saline (PBS) only) had no harmful effect on the developing limb (Fig. 1A,B) . Beads containing 660 mg/ml recombinant human BMP2 (rBMP2), however, caused severe degeneration of the tissue around the bead, leading to a constriction at this point in an almost normalised limb (Fig. 1C) . There was no chondrogenesis beyond the shoulder girdle condensation in the treated limb bud at this stage, resulting in a gap between shoulder girdle and bead (Fig. 1C) . At half this concentration, rBMP2 caused a reduction in the size of the humerus (Fig. 1D ) in five out of five cases showing that, at these doses, the effect was concentration dependent.
Application of rBMP4 (330 mg/ml) resulted in complete degeneration of the developing limb (Fig. 1E,F) . It therefore had a greater effect than BMP2 (at least with the particular preparations we were using). This degree of degeneration could also be achieved at a dosage level of 200 mg/ml (Fig .  1G ) and so this concentration was used in all subsequent experiments. Usually no chondrogenesis was observed, but occasionally (two out of twelve) shoulder girdle condensa- Fig. 2 . Cell death in BMP4-treated limb buds. Beads charged with (A) PBS, (B) 200 mg/ml rBMP4, (C) 400 mg/ml rFGF4 and 200 mg/ml rBMP4, were implanted into stage 20-22 chick limb buds and fixed 24 h later (stages 25-26). Limbs treated with BMP4 beads were approximately half the size of the control limb at this time. Transverse sections cut through the level where the beads were located were subjected to the TUNEL assay for DNA degradation. Left hand panels, haematoxylin/eosin stained sections and FITC-stained dead cells; scale bar, 500 mm. Right hand panels, ×2 enlargements of FITC-stained limb buds. The apoptosis triggered by rBMP4 application was inhibited by rFGF4 at a dose twice that of the rBMP4. tions developed. The limb bud continued to grow after bead implantation, but after one day post-implantation, degeneration had started. The degree of apoptosis was assessed using the terminal transferase assay (TUNEL) (Gavrieli et al., 1992) . The beads without growth factors ( Fig. 2A) did not cause any additional cell death, whereas beads soaked in 200 mg/ml rBMP4 caused considerable cell death throughout the limb bud and some of the adjacent tissue (Fig. 2B) .
rFGF4 can rescue normal development in limb buds treated with rBMP4
Bmp4 mRNA is produced by most of the mesenchyme of the stage 18-19 chick limb bud . Assuming that this is successfully translated and that the necessary receptors are present to transduce the signal, there must be some inhibition of the apoptotic activity of the BMP4 protein in this mesenchyme. As FGF4 can replace the AER in stages 20-22 limb buds in producing normal outgrowth, and it (along with FGF8) overlies the Bmp2 and Bmp4 expression domains in the progress zone, FGF4 was tested for such an activity. Beads soaked in a 2:1 ratio of rFGF4:rBMP4 (400:200 mg/ml) were able to prevent apoptosis from occurring ( Fig. 2C) and to rescue normal development ( Fig. 3A and Table 1 ). The duplicate example shown in Fig. 3B is classed as 'normal' despite having only one chondrogenic condensation in the forearm, as digit condensations are clearly being laid down. In three cases, rescue was incomplete, with evidence of humerus condensations but no radius, ulna or autopod condensations (Table 1) .
If these growth factors were delivered in separate beads, the results were much more variable, with only five out of the twelve rFGF4 beads capable of rescuing the condition (Fig. 3C,D) , five of partial rescue, and two similar to the positive controls, that is, no limb structures having developed beyond a shoulder girdle condensation (Table 1 ). Therefore rescue was still possible when the factors were delivered separately, and had overlapping, but not identical distributions. Fig. 3 . Rescue of BMP4-mediated degeneration by FGF4. Each row contains duplicate embryos (A,B.) each with a bead containing 400 mg/ml rFGF4 and 200 mg/ml rBMP4, (C,D) with the same concentration growth factors administered in separate beads, (E,F) with a single bead containing 200 mg/ml of both growth factors, implanted at stages 20-22. Two days later (stages 27-28) the embryos were fixed and stained with Alcian blue. A similar degree of outgrowth was achieved with a high dose of FGF4 as in the control limbs (left hand side). Lower concentrations were not sufficient to achieve this. Scale bar, 1000 mm.
If, as these results suggest, FGF4 is alleviating the deleterious effect of BMP4, then it should be possible to titrate out this activity of FGF4 by simply reducing the amount of rFGF4 loaded into the beads. When beads containing a 1:1 ratio (200:200 mg/ml) of the two growth factors were implanted in limb buds, the abnormalities produced were similar to the severest effect seen with rBMP2 ( Fig. 1B) , that is, a normal-sized limb, but a constriction of the tissue around the bead, with very little (or no) chondrogenesis beyond the shoulder girdle condensation (Fig.  3E,F) .
rBMP4 causes chondrogenesis in 5-day chick limb buds
Because BMPs promoted apoptosis in the early limb bud, we were interested to determine the duration of the window when BMPs have deleterious effects on limb development. Beads loaded with 200 mg/ml rBMP4 were implanted in the limb buds of 5-day chick embryos (stages 25-26), and left for a further day (stages 27-28) before staining with Alcian blue. Under these conditions, that is, implanting the bead just one day after BMPs disrupt limb development, rBMP4 caused intense chondrogenesis to occur in six out of six cases (Fig. 4A,B) . The chondrogenesis was usually, but not always, around the bead, which merely reflects the central location within the limb bud of most of the beads.
rFGF4 inhibits chondrogenesis
Beads loaded with a 2:1 ratio of rFGF4 and rBMP4 (400:200 mg/ml, respectively) and implanted into the core of stage 25-26 wing buds, generally caused little change in limb morphology (three out of five cases; Fig. 4E ) although in some embryos there was evidence of either extra or reduced chondrogenesis (e.g. Fig. 4F ). Beads containing just rFGF4 caused a reduction in chondrogenesis in the area where the bead had been implanted in six out of eight cases (Fig. 4C,D) , indicating FGF4 can block cells from undergoing chondrogenesis.
Discussion
The fact that FGF4 and BMP2 have antagonistic activities has been shown previously, where BMP2 was shown to inhibit the effect of FGF4 on proliferation of mesenchyme cells in a mouse limb bud assay . These findings have recently been extended to show that BMP2 and BMP4 can inhibit the ability of FGFs to induce Pax9 expression in the mandibular and maxillary arches, which determines the position of formation of individual teeth (Neübuser et al., 1997) . Here we show the reverse, namely, that FGF4 can inhibit the ability of BMP4 to induce apoptosis and chondrogenesis in the chick limb bud.
BMP4 and apoptosis during limb bud development
Bmps are expressed in the anterior and posterior necrotic zones of the stage 23-25 chick wing bud , and as they have been shown to promote apoptosis of neural crest cells in rhombomeres 3 and 5 of the stage 9 chick hindbrain (Graham et al., 1994) , they have also been implicated in the cell death that occurs in the necrotic zones of the limb buds. Here, we show that ectopic application of BMP2 and BMP4 to the core of stage 20-22 chick limb buds can cause severe apoptosis, leading to complete degeneration of the limb bud. The doses of growth factors used here are similar to those used in other in vivo bead implant experiments, such as in the application of the FGF4 in the AER replacement experiments of and in the dose of BMPs required to achieve expression levels similar to those of the endogenous Msx genes on ectopic application to cranial mesenchyme (Barlow and Francis-West, 1997) .
Apoptosis also occurs in the interdigital regions of the hand-and footplates, and both the direct application of BMP4 (Gañan et al., 1996) , and dominant negative mutations introduced into Bmpr-1A and Bmpr-1B indicate that BMPs are instrumental in causing apoptosis in the interdigital regions (Zou and Niswander, 1996; Yokouchi et al., 1996) .
The sequence of limb development in the chick has been established by sequential removal of the AER (Saunders, 1948; Summerbell et al., 1973) . Until stage 23 this initially results in a certain degree of apoptosis in the progress zone (Rowe et al., 1982) . We have shown here that the transition period between the early action of BMP4 (apoptosis) and the late function (chondrogenesis) is between stages 23 and 24. At this time also, expression of Bmp4 is ceasing at the distal tip of the progress zone . As AER function can be performed by exogenously-applied FGF4, withdrawal from the effects of FGF4 has, until now, seemed the most likely explanation for the apoptosis resulting from AER removal. Our experiments, however, suggest that BMPs in the mesenchyme are responsible for this, and that their action is normally suppressed in the progress zone by FGF4, or by other fibroblast growth factors that are expressed during limb bud development (Munaim et al., 1988; Crossley et al., 1996; Ohuchi et al., 1997) . This novel aspect of epithelial-mesenchymal interactions may apply to other signalling centres during development.
Induction of chondrogenesis
Implanting the BMP4 beads a day later, between stages 25 and 26, caused intense chondrogenesis. Once again this effect was inhibited by FGF4. Stasis is achieved at a 2:1 ratio of FGF4 to BMP4, which is a 1:1 ratio in terms of molecules. This time the FGF4 appears to be directly inhibiting chondrogenesis. This data is consistent with the phenotype of the Fgfr-3 targeted null mutation in mice (Colvin et al., 1996; Deng et al., 1996) where mutant embryos have enlarged long bones of the limbs and large vertebrae. The primary defect of these mice is an increase in chondrocyte production. This indicates that FGFs have a role in negatively regulating bone size during normal development. Confirmation of this comes from the finding that achondroplasia, the most common form of dwarfism, is the result of dominant negative mutations of Fgfr-3 (Shiang et al., 1994) . The lack of an embryo phenotype may be a result of functional overlap between FGF receptors, because although the three FGF receptors that affect bone growth have reasonably distinct expression patterns within developing bone, with a major part of the expression of Fgfr-1 being in the periostium, that of Fgfr-2 in the hypertrophic cartilage, and that of Fgfr-3 in the resting cartilage, there is considerable overlap of expression in the chondrocyte condensations of the early limb bud (Orr-Urtreger et al., 1991; Peters et al., Fig. 4 . The effects on chondrogenesis of BMP4 and FGF4 when applied to limb buds of 5-day-old (stages 25-26) embryos. Beads containing (A,B) 200 mg/ml rBMP4, (C,D) 400 mg/ml rFGF4, (E,F) 400 mg/ml rFGF4 and 200 mg/ml rBMP4 were implanted into the limb buds of stages 25-26 chick embryos. The following day (stages 27-28) embryos were fixed and stained with Alcian blue. While BMP4 prompted cartilage formation, FGF4 prevented it. A mixture of these growth factors in a ratio of 2:1 allowed normal development. Scale bar, 1000 mm.
1992, 1993). The ectopic application of rFGF4 described here, being the equivalent of a localised over-expression regime, clearly shows that FGF4 can act negatively on cartilage formation at the earliest stages of bone formation.
The BMP type I receptors have distinct but also overlapping functions in bone formation, both being involved in cartilage production, but Bmpr-1B appearing to be more involved in initiating the chondrocyte lineage, and the Bmpr-1A in its differentiation (Zou et al., 1997) . The receptors of both families of growth factor are therefore present and functional in the developing cartilage rudiments, and could act antagonistically during this process to control the size of the chondrocyte progenitor cell pool and hence the size of limb bones in proportion to other structures in the body of the early embryo.
Experimental procedures
Chick embryos
Fertile eggs were supplied by the Roslin Institute, (Roslin, Midlothian, UK) and were incubated at 37°C in a humidified incubator, with daily turning, for the time required to produce the desired stage (Hamburger and Hamilton, 1951 ) of development.
Loading beads
Heparin acrylic beads (Sigma, H5263) were washed in several changes of Dulbecco A solution (PBS) then transferred to a 2 ml drop of growth factor solution . All human recombinant growth factors were generously supplied by the Genetics Institute, (Boston, MA) and when necessary were diluted with PBS/0.1% bovine serum albumin (BSA) immediately prior to use. Beads were embedded into the mesenchyme of limb buds through slits that had been scored with tungsten dissection needles. Egg windows were re-sealed with sellotape and the eggs returned to the incubator for the desired length of time.
Alcian blue staining
This was carried out essentially according to Shum et al. (1993) . Here, embryos were fixed and stained simultaneously in a solution of ethanol:glacial acetic acid (4:1) containing 0.15 mg/ml Alcian blue powder. After 24-48 h the embryos were gradually hydrated through a series of ethanol washes and cleared in 0.1 M potassium hydroxide. They were stored in 25% ethanol and 50% glycerol.
TUNEL reactions
DNA fragmentation was assayed using terminal transferase (Gavrieli et al., 1992) . 6-mm thick tissue sections were cut from paraffin wax blocks using standard techniques.
After xylene washes to remove the wax, and rehydration, TUNEL reactions were performed according to Müller et al. (1995) using Boehringer (Mannheim, Germany) transferase enzyme and FlTC-dUTP.
